CTLA4 and neoplasm: Building on this, another study showed that VSV-NDV synergizes with immune checkpoint blockade (anti-CTLA-4), enhancing tumor-specific T cell activation via tumor RIG-I signaling, which was critical for the combined therapeutic effect [43].